NCT05334251

Brief Summary

Anesthesia management in colon cancer surgery affects the postoperative mobilization, discharge and oral intake times of the patients. Due to the side effects of opioids, their use is tried to be reduced and therefore regional anesthesia methods are preferred in suitable patients. Especially in the preoperative period, opioid use has a negative effect on the recovery processes, morbidity and mortality of the patients. Epidural analgesia, a central block method, is recommended for postoperative pain control in ERAS protocols. Opioids suppress cellular and humoral immunity. Epidural analgesia reduces both opioid consumption and surgical stress response. It has been shown that epidural analgesia maintains the immune functions of patients and is associated with a decrease in tumor recurrence. It has also been shown to reduce postoperative pain, hypercoagulability and pulmonary complications, increase exercise capacity and accelerate the return of intestinal functions to normal. In line with this information, in this study, it was aimed to investigate the differences in the postoperative period in patients managed with regional anesthesia. In the study, it was planned to create two groups who underwent open surgery for colon cancer. The first group will be operated under general anesthesia and the second group will be operated under combined spinal-epidural anesthesia with ketofol sedation. An epidural catheter will be inserted in both groups for postoperative pain management. In the study, patients' age, gender, weight, comorbidity, ASA score, amount of local anesthetic used, postoperative VAS scores, mobilization time, time to start oral intake, nasogastric withdrawal time, drain removal time, urinary catheter withdrawal time, hospitalization time and total cost will be evaluated.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2022

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 19, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

April 1, 2022

Completed
18 days until next milestone

First Posted

Study publicly available on registry

April 19, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2023

Completed
Last Updated

April 19, 2022

Status Verified

April 1, 2022

Enrollment Period

11 months

First QC Date

November 19, 2021

Last Update Submit

April 12, 2022

Conditions

Outcome Measures

Primary Outcomes (19)

  • visual analog scale (VAS)

    A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 5 cm horizontal line (between 0 and 5 points, 0 meaning 'no pain' and 5 meaning the worst) and this rating is then measured from the left edge (=Visual Analog Scale score).

    postoperative 2nd hour.

  • visual analog scale (VAS)

    A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 5 cm horizontal line (between 0 and 5 points, 0 meaning 'no pain' and 5 meaning the worst) and this rating is then measured from the left edge (=Visual Analog Scale score).

    postoperative 4th hour.

  • visual analog scale (VAS)

    A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 5 cm horizontal line (between 0 and 5 points, 0 meaning 'no pain' and 5 meaning the worst) and this rating is then measured from the left edge (=Visual Analog Scale score).

    postoperative 8th hour.

  • visual analog scale (VAS)

    A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 5 cm horizontal line (between 0 and 5 points, 0 meaning 'no pain' and 5 meaning the worst) and this rating is then measured from the left edge (=Visual Analog Scale score).

    postoperative 12th hour.

  • visual analog scale (VAS)

    A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 5 cm horizontal line (between 0 and 5 points, 0 meaning 'no pain' and 5 meaning the worst) and this rating is then measured from the left edge (=Visual Analog Scale score).

    postoperative16th hour.

  • visual analog scale (VAS)

    A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 5 cm horizontal line (between 0 and 5 points, 0 meaning 'no pain' and 5 meaning the worst) and this rating is then measured from the left edge (=Visual Analog Scale score).

    postoperative 24th hour.

  • time to start oral intake

    the time the patient start to consume orally after the operation

    to be observed until the start of oral intake after the operation. it will be assessed up to 720 hours.

  • mobilization time

    the time the patient was start to walk after the operation

    to be observed until the start of walking after the operation. it will be assessed up to 720 hours.

  • urinary catheter withdrawal time

    the time the urinary catheter was withdrawn after the operation

    to be observed until the withdrawal of urinary catheter after the operation. it will be assessed up to 720 hours.

  • hospitalization time

    The time from the day the patient was hospitalized before the operation to the day of discharge after the operation.

    from hospitalization for the operation to the day of discharge, it will be assessed up to 30 days.

  • nasogastric withdrawal time

    the time the nasogastric tube was withdrawn after the operation.

    to be observed until the withdrawal of nasogastric tube after the operation. it will be assessed up to 720 hours.

  • drain removal time

    the time the abdominal drain was withdrawn after the operation.

    to be observed until the withdrawal of abdominal drain after the operation. it will be assessed up to 720 hours.

  • complications

    all complications related with surgery or anesthesia

    to be observed for 30 days postoperatively.

  • blood pressure

    patients' mean arterial pressure levels

    preoperatively

  • blood pressure

    patients' mean arterial pressure levels

    perioperatively. "30 minutes" will be taken as the measurement period.

  • FiCO2

    inspiratory carbondioxide level

    preoperatively

  • FiCO2

    inspiratory carbondioxide level

    perioperatively. "30 minutes" will be taken as the measurement period.

  • sPO2

    oxygene saturation

    preoperatively

  • sPO2

    oxygene saturation

    perioperatively. "30 minutes" will be taken as the measurement period.

Study Arms (2)

general anesthesia group

Patients in this group will undergo open colon cancer surgery under general anesthesia. Epidural catheterization will be applied for postoperative analgesia.

combined spinal-epidural anesthesia group

Patients in this group will undergo open colon cancer surgery under combined spinal-epidural anesthesia with ketofol sedation. Epidural catheterization will be applied for postoperative analgesia.

Other: combined spinal-epidural anesthesia

Interventions

Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.

combined spinal-epidural anesthesia group

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients over 40 years of age who are scheduled for open surgery with a diagnosis of colon cancer.

You may qualify if:

  • Patients over 40 years of age who are scheduled for open surgery with a diagnosis of colon cancer

You may not qualify if:

  • Local anesthetic allergy
  • Patients scheduled for laparoscopic surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Wu HL, Tai YH, Mandell MS, Tsou MY, Yang SH, Chen TH, Chang KY. Effect of epidural analgesia on cancer prognosis after colon cancer resection: a single-centre cohort study in Taiwan. BMJ Open. 2020 Oct 22;10(10):e036577. doi: 10.1136/bmjopen-2019-036577.

    PMID: 33093029BACKGROUND
  • Cummings KC III, Zimmerman NM, Maheshwari K, Cooper GS, Cummings LC. Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth. 2018 Jun;47:12-18. doi: 10.1016/j.jclinane.2018.03.005. Epub 2018 Mar 12.

    PMID: 29544203BACKGROUND
  • Ljungqvist O, Hubner M. Enhanced recovery after surgery-ERAS-principles, practice and feasibility in the elderly. Aging Clin Exp Res. 2018 Mar;30(3):249-252. doi: 10.1007/s40520-018-0905-1. Epub 2018 Feb 16.

    PMID: 29453605BACKGROUND
  • Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, Rockall TA, Young-Fadok TM, Hill AG, Soop M, de Boer HD, Urman RD, Chang GJ, Fichera A, Kessler H, Grass F, Whang EE, Fawcett WJ, Carli F, Lobo DN, Rollins KE, Balfour A, Baldini G, Riedel B, Ljungqvist O. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS(R)) Society Recommendations: 2018. World J Surg. 2019 Mar;43(3):659-695. doi: 10.1007/s00268-018-4844-y.

    PMID: 30426190BACKGROUND

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Central Study Contacts

Ayça Tuba Dumanlı Özcan, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, MD

Study Record Dates

First Submitted

November 19, 2021

First Posted

April 19, 2022

Study Start

April 1, 2022

Primary Completion

March 1, 2023

Study Completion

April 1, 2023

Last Updated

April 19, 2022

Record last verified: 2022-04